Filing Flows › Xenetic Biosciences (XBIO) › Q3 2025
Xenetic Biosciences (XBIO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Xenetic Biosciences (XBIO) reported revenue of $1.0M for the third quarter 2025 (Q3 2025), +67% from a year earlier and +74% from the quarter before. Operating margin was -53.0%, net loss $510K (49.7% of revenue).
Xenetic Biosciences, Q3 2025: revenue $1.0M (+67% year over year), operating margin -53.0%, net loss $510K, operating cash flow −$658K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | +74% | +67% |
| Operating profit | −$545K | — | — |
| Net earnings | −$510K | — | — |
| Operating cash flow | −$658K | — | — |
What changed
Revenue was $1.0M in Q3 2025, up 67% year over year and up 74% from the previous quarter.
Operating costs exceeded revenue by $545K, an operating margin of -53.0%. Total costs grew 41% against revenue growth of 67%. The fastest-growing cost line was Research & development (+106%). The quarter ended with a net loss of $510K, narrower than the previous quarter's $689K loss.
Operating cash flow was −$658K. Non-cash charges added back $16K of share-based compensation. Working capital and other items used $164K.
Questions
What was Xenetic Biosciences' revenue in the third quarter 2025?
Xenetic Biosciences (XBIO) reported revenue of $1.0M for the third quarter 2025 (Q3 2025), +67% from a year earlier and +74% from the quarter before.
Was Xenetic Biosciences profitable in the third quarter 2025?
Operating loss was $545K (-53.0% of revenue) and net loss $510K.